Starpharma's Radiotherapeutics and Telix's Molecularly Targeted Radiation platform

Starpharma has many irons in the fire

One of them is Dep Radiotherapeutics which targets (locates) cancer zones in the body and delivers its anti cancer drugs to the relevant site

Telix's Molecularly Targeted Radiation platform highlights cancer cells in body....and that's it!

Telix could be an off-shoot of Starpharma. It's market cap (TLX) is currently $331 million

So the question posed....with the main technology of Telix being Molecularly Targeted Radiation and Starpharma having this and destroying the underlying cancer in situ....... as being just one of many solutions for cancer in its pipeline......surely the multi billion potential value of Starpharma is (as an understatement).....severely undervalued